Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Colorectal Neoplasms 7Pancreatic Neoplasms 4Rectal Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Resectable MMR-deficient Solid Tumors 1Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Microsatellite Stable Rectal Carcinoma 1Lymphoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Adenocarcinoma 1

Interventions

pembrolizumab 3Temozolomide 3Specimen Handling 3Radiotherapy 2peposertib 1liposomal doxorubicin 1gosha-jinki-gan 1efineptakin alfa 1cabozantinib 1balstilimab 1atezolizumab 1abexinostat 1Surgical Procedures, Operative 1Radiation 1ONC206 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Gliosarcoma × balstilimab × Clear all
NCT05864534 2026-05-13

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Northwestern University

Phase 2 Recruiting
25 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡